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Abstract
The standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiotherapy (CCRT). Although the
activated PI3-kinase/Akt pathway is known to be involved in both cisplatin-resistance and radioresistance, to date, only a few studies
have reported signiﬁcant associations between PIK3CA genemutational status and outcome by CCRT in the disease. The aim of this
study was to clarify the prognostic signiﬁcance of PIK3CA mutational status in cervical cancers treated by CCRT.
We analyzed PIK3CA mutation in 59 patients with stage IIB to IVA cervical carcinomas primarily treated by CCRT with weekly
cisplatin using formalin-ﬁxed parafﬁn-embedded biopsy specimens before treatment. Fifty-seven of 59 patients (97%) had locally
advanced cancers with stage IIIA to IVA. Clinicopathologic data and patient survival were retrospectively compared according to
PIK3CA mutational status.
PIK3CAmutation was found in 7 of 59 patients (12%). No signiﬁcant differences in clinicopathologic characteristics were observed
according to PIK3CA mutational status. Patients with wild-type PIK3CA showed signiﬁcantly improved cancer-speciﬁc survival as
compared with mutated patients (P= .044). Subsequent survival analyses revealed that PIK3CA mutation was a signiﬁcant
prognostic factor for poor overall survival [multivariate adjusted hazard ratio (HR), 3.9; 95% conﬁdence interval (95% CI), 1.3–11.8;
P= .017] and cancer-speciﬁc survival (multivariate adjusted HR, 3.6; 95% CI, 1.2–11.0; P= .024).
Together with previous published ﬁndings, the current study further supports the clinical signiﬁcance of PIK3CAmutation in cervical
cancer. Our observations suggest that molecular inhibitors targeting the PI3-kinase/Akt pathwaymay improve the outcome by CCRT
in cervical cancers harboring PIK3CA mutation, providing signiﬁcant implications for novel treatment strategy based on precision
medicine in the disease.
Abbreviations: ABD = adaptor-binding domain, CCRT = concurrent chemoradiotherapy, CI = conﬁdence interval, cSH2 = C-
terminal SH2, CSS = cancer-speciﬁc survival, DNA-PK = DNA-dependent protein kinase, FFPE = formalin-ﬁxed, parafﬁn-
embedded, FIGO = International Federation of Gynecology and Obstetrics, HR = hazard ratio, iSH2 = inter-SH2, nSH2 = N-terminal
SH2, OS= overall survival, PDK1= phosphoinositide-dependent kinase 1, PFS= progression-free survival, PI3K= phosphoinositide
3-kinase, PIP2 = phosphatidylinositol-4,5-bisphosphate, PIP3 = phosphatidylinositol-3,4,5-triphosphate, RBD = Ras-binding
domain.
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1. Introduction
Incidence and mortality of cervical cancer are both the 4th in
women worldwide, and cervical cancer causes 7.5% of all female
cancer deaths (CANCERTODAY; http://gco.iarc.fr/today/home).
Although current standard treatment for locally advanced cervical
cancer is cisplatin-based concurrent chemoradiotherapy (CCRT),
the 5-year survival rate in advanced cervical cancer patients is still
low (30–50%). Hence, the development of novel treatment
strategy to improve outcome by CCRT is urgently required.
PIK3CA mutation is reportedly the most common genetic
alteration in cervical cancers, followed by KRAS, EGFR, and
thenPTEN loss.[1] Thirteen to36%of cervical cancers are reported
to harbor PIK3CA mutations.[2]PIK3CA gene encodes p110a
protein, the catalytic subunit of phosphoinositide 3-kinase (PI3K),
and is known to be mutated or ampliﬁed in many kinds of human
cancers. The PI3K/Akt signaling is one of the pivotal pathways for
human carcinogenesis. Binding of growth factors phosphorylates
and activates the tyrosine kinase receptor on cell membrane. The
active receptor then turns on the PI3K enzyme attached at its
bottom, and PI3K phosphorylates phosphatidylinositol-4,5-
bisphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate
(PIP3). PIP3 activates phosphoinositide-dependent kinase 1
(PDK1) enzyme that will phosphorylate and activate Akt. The
activated Akt will then regulate downstream components neces-
sary for a variety of cellular functions, including cell cycle,
apoptosis, protein synthesis, DNA damage repair, and angiogene-
sis. Besides, the PI3K/Akt pathway is known to be involved in
resistance to cisplatin. Akt is reported to induce cisplatin resistance
through inhibiting the downstream proteins such as p21, Mdm2,
Bad, Bax, andCaspases.[3] The PI3K/Akt pathway is alsoknown to
be involved in radioresistance through the following mecha-
nisms.[4] The PI3K/Akt pathway regulates DNA-dependent
protein kinase (DNA-PK), which is responsible for the repair of
DNA double-strand breaks caused by irradiation. In addition,
inhibiting the PI3K/Akt pathway downregulates hypoxia-induc-
ible factor 1-a and vascular endothelial growth factor, resulting in
normalized vasculature and decreased hypoxia. However, to date,
only a few studies have reported the prognostic signiﬁcance of
PIK3CAmutation in cervical cancers treated by CCRT. McIntyre
et al[5] reported that overall survival (OS) at 5 years after CCRT
was signiﬁcantly worse for PIK3CA mutant patients compared
with PIK3CA wild-type patients (40% vs 70%). In another study
conducted by Wang et al,[2] patients with PIK3CA mutations
had a signiﬁcantly lower complete response rate to CCRT, 52%
against 86% in PIK3CA wild type. Further accumulation of
evidence is warranted to clarify the prognostic signiﬁcance of
PIK3CAmutation for the outcome after CCRT. Hence, the aim of
the current study was to clarify the prognostic signiﬁcance of
PIK3CA mutational status in cervical cancers treated by CCRT
with weekly cisplatin. We demonstrate here that PIK3CA
mutation was a signiﬁcant prognostic factor for poor OS and
cancer-speciﬁc survival (CSS) after CCRT. Our ﬁndings provide
signiﬁcant implications for a novel treatment strategy for cervical
cancer.
2. Materials and methods
2.1. Patients and treatment
Patients with cervical carcinomas who were primarily treated by
CCRT with weekly cisplatin at the University of Tsukuba
Hospital between 2001 and 2015 were identiﬁed through our
database, and their medical records were retrospectively
reviewed. Staging at diagnosis was performed on the basis of
the International Federation of Gynecology and Obstetrics
(FIGO) system. Patients mostly received whole pelvic irradiation
of 50Gy and brachytherapy of 24Gy concomitant with 5 to 6
cycles of weekly administration of 40mg/m2 cisplatin. All
samples were obtained with informed consent or opt-out
procedure in accordance with protocols approved by the Ethics
Committee University of Tsukuba Hospital. Median follow-up
duration was 77 months. Follow-up data were retrieved until
June 30, 2017. Table 1 summarizes patient characteristics.
2.2. DNA extraction and PIK3CA mutation analysis
Genomic DNAs were extracted from formalin-ﬁxed, parafﬁn-
embedded (FFPE) biopsy specimens before treatment using
blackPREP DNA Kit (GenoStaff, Tokyo, Japan) according to the
manufacturer’s instruction. Mutation analysis of PIK3CA gene
was performed as described previously.[6]
2.3. Statistical analyses
Differences in proportions were evaluated by the Fisher exact test.
Differences in continuous variables were evaluated by the t test.
Kaplan–Meier survival curves were calculated and compared
statistically using the log-rank test. The Cox proportional hazard
Table 1
Patient characteristics.
Characteristic Number (n=59)
Mean age (range), y 51.3 (28–75)
FIGO stage (%)
IIB 2
IIIA 2
IIIB 52
IVA 3
Histology
Squamous cell carcinoma 53
Poorly differentiated carcinoma 2
Adenocarcinoma 2
Mucinous adenocarcinoma 1
Adenosquamous carcinoma 1
Pelvic node metastasis
Present 39
Absent 20
Paraaortic node metastasis
Present 13
Absent 46
Response
CR 44
PR 10
SD 1
PD 4
Recurrence
No 29
Yes 25
Persistent disease 5
Recurrent site
Inside the irradiated ﬁeld 13
Outside the irradiated ﬁeld 15
Both 2
PIK3CA mutation
Wild type 52
Mutated 7
CR= complete response, FIGO= International Federation of Gynecology and Obstetrics, PD=
progressive disease, PR=partial response, SD= stable disease.
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model was used for univariate analysis and, after adjustment for
baseline characteristics and prognostic factors (age, FIGO stage,
histology, and pelvic node metastasis), multivariate analysis.
3. Results
We analyzed DNA sequences on exons 9 and 20 of the PIK3CA
gene in archival FFPE biopsy specimens before treatment by
direct sequencing in 59 patients with stage IIB to IVA cervical
carcinomas treated by CCRT with weekly cisplatin. Among the
patients, 57 (97%) were locally advanced cancers (Table 1). We
found PIK3CAmutation in 7 of 59 patients (12%). Five (71%) of
the mutations were mapped on the helical domain, and 1 (14%)
on the kinase domain of the p110a protein (Table 2). We next
compared various clinicopathologic features according to
PIK3CA mutational status, ﬁnding no signiﬁcant differences in
any of the variables, including age, FIGO stage, histologic
subtype, and response rates after CCRT (Table 3). Subsequently,
we compared CSS according to various prognostic factors
including PIK3CA mutational status (Fig. 1). Pelvic node
metastasis showed a difference without statistical signiﬁcance
(P= .053; Fig. 1E). Interestingly, PIK3CAmutation was the only
prognostic factor showing a signiﬁcant associationwith poor CSS
(5-year survival rate: 64% vs 43%; P= .044; Fig. 1A). We also
compared OS and progression-free survival (PFS) according to
PIK3CA mutational status, but both differences were not
signiﬁcant (5-year survival rate: 64% vs 43% and 52% vs
21%; P= .055 and .29, respectively; Fig. 2A, B). Finally, we
conducted univariate and multivariate analyses of PIK3CA
mutation for survival (Table 4). Notably, adjusted multivariate
analysis demonstrated that PIK3CAmutation was signiﬁcant for
poor OS [hazard ratio (HR), 3.9; 95% conﬁdence interval (95%
CI), 1.3–11.8; P= .017; Table 4] and CSS (HR, 3.6; 95%CI, 1.2–
11.0; P= .024; Table 4), but not for poor PFS (HR, 2.3; 95% CI,
0.81–6.5; P= .12; Table 4).
4. Discussion
Our mutational analysis found PIK3CAmutations in 12% of the
patients, which is relatively lower than the results previous
reported (13–36%;[2]), possibly due to difference in quality of
samples for DNA extraction, as we used archival FFPE biopsy
specimens from patients with mostly locally advanced cancers
before treatment. PI3K is a heterodimer of the catalytic subunit
p110a and the regulatory subunit p85a. P110a is composed of 5
domains: an adaptor-binding domain (ABD; residues 16–105), a
Ras-binding domain (RBD; residues 187–289), a C2 domain
(residues 330–487), a helical domain (residues 517–694), and a
kinase domain (residues 797–1068). P85a also comprises 5
domains: an SH3 domain, a GAP domain, an N-terminal SH2
(nSH2) domain, an inter-SH2 domain (iSH2), and a C-terminal
SH2 domain (cSH2). All of themutations found in our studywere
mapped inside the helical or kinase domains of p110a (Table 2).
E542 and E545 on the helical domain are suggested to
biochemically interact with K379 and R340 of the nSH2 of
p85.[7,8] Moreover, the crystal structure of p110a/p85a complex
reportedly showed that E542 and E545 are located at the
interface with nSH2 in close proximity to the nSH2-kinase
domain interface, suggesting a mechanism whereby E542K and
E545K mutations can affect the enzyme activity of p110a.[9]
T1025 was shown to be located close to the N-terminus of the
catalytic loop, and may therefore alter the enzyme activity
through changing the conformation of the catalytic loop.[9] On
the basis of these structural information, we regard that
considerable translational signiﬁcance lies in our subsequent
analyses on the associations between PIK3CA mutational status
and clinicopathologic data.
Our subsequent survival analyses revealed that patients with
mutant PIK3CA had signiﬁcantly worse CSS than those with
wild type, and that PIK3CA mutation was a signiﬁcant
prognostic factor for poor OS and CSS. As regards the prognostic
impact of PIK3CA mutation, McIntyre et al [5] previously
reported that PIK3CAmutational status was strongly associated
with OS in FIGO stage IB/II patients, but not in stage III/IVA
patients (P= .0002 vs P= .98). However, most of the patients in
our study were stage III/IVA (97%; Table 1). Likewise, Wang
et al[2] reported that patients without genetic alterations
(mutations or ampliﬁcation) of PIK3CA had a signiﬁcantly
higher response rate than those with the alterations (P= .006);
however, our study did not ﬁnd any difference in the response
rate (Table 3). These discrepancies among studies may be
Table 2
Results of PIK3CA mutation analysis.
Nucleotide Amino acid Exon Domain
1 1571G>A R524K 9 Helical
2 1624G>A E542K 9 Helical
3 1624G>A E542K 9 Helical
4 1633G>A E545K 9 Helical
5 1633G>A E545K 9 Helical
6 1634A>C E545A 9 Helical
7 3073A>G T1025A 20 Kinase
Table 3
Relationship between PIK3CAmutational status and clinicopatho-
logic variables.
PIK3CA
Clinicopathologic variable Wild type Mutated P
Mean age (range), y 51.3 (28–75) 51.1 (29–68) .97
FIGO stage
IIB 1 (2%) 1 (14%)
IIIA 2 (4%) 0 (0%)
IIIB 46 (88%) 6 (86%)
IVA 3 (6%) 0 (0%) .43
Histology
Squamous cell carcinoma 46 (88%) 7 (100%)
Others 6 (12%) 0 (0%) 1.0
Pelvic node metastasis
Present 35 (67%) 4 (57%)
Absent 17 (33%) 3 (43%) .68
Paraaortic node metastasis
Present 12 (23%) 1 (14%)
Absent 40 (77%) 6 (86%) 1.0
Response
CR/PR 47 (90%) 7 (100%)
SD/PD 5 (10%) 0 (0%) 1.0
Recurrence
No 27 (52%) 2 (29%)
Yes 20 (38%) 5 (71%)
Persistent disease 5 (10%) 0 (0%) .30
Recurrent site
Inside the irradiated ﬁeld 12 (48%) 1 (20%)
Outside the irradiated ﬁeld 11 (44%) 4 (80%)
Both 2 (8%) 0 (0%) .54
CR= complete response, FIGO= International Federation of Gynecology and Obstetrics, PD=
progressive disease, PR=partial response, SD= stable disease.
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attributed to differences in analyzed genetic alterations (including
or not ampliﬁcation), constitution of histological subtypes
(including or not other than SCC) and FIGO stages, patient
follow-up durations, and/or recurrence treatment strategies. In
any case, the current ﬁndings further support the signiﬁcance of
PIK3CA genetic aberrations on outcome of cervical cancers
treated by CCRT.
The results of our survival analyses are suggestive of a
possibility that inhibiting PI3K by molecular targeting agents
may improve outcome by CCRT with cisplatin. Regarding the
effect of PI3K inhibitor combined in the treatment of cervical
cancer, there have been some preclinical studies reported. Xie
et al [10] have recently reported that a dual PI3K/mTOR inhibitor
NVP-BEZ235 treatment in combination with cisplatin or
carboplatin induced a synergistic antitumor response in cervical
carcinoma cells in vitro. Likewise, PI3-kinase inhibitor
LY294002 reportedly radiosensitized cervical cancer cell lines
in vitro[11] and in vivo.[12] Moreover, Arjumand et al[13] recently
examined in vitro whether mutated PIK3CA confers cervical
cancer cells higher resistance to cisplatin and/or radiation, and
whether this phenotype is reversed by inhibiting PI3K. They
reported that CaSki cells harboring heterozygous E545K were
PIK3CA wild type
PIK3CA mutated
Age>60
Age<60
FIGO stage IV
FIGO stage II
p=0.51
p=0.52
SCC
Others
p=0.053
Pelvic node metastasis (-)
Pelvic node metastasis (+)
p=0.94
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Figure 1. Kaplan–Meier curves for cancer-speciﬁc survival in cervical cancers treated by CCRT. (A) Cases with wild-type PIK3CA (n=52) versus mutant PIK3CA
(n=7); (B) Cases with age60 years (n=43) versus age>60 years (n=16); (C) Cases with FIGO stage II (n=2) versus III (n=54) versus IV (n=3); (D) Cases with
squamous cell carcinomas (n=53) versus other histologic types (n=6); (E) Cases with negative pelvic node metastasis (n=20) versus positive pelvic node
metastasis (n=39); (F) Cases with negative paraaortic node metastasis (n=46) versus positive paraaortic node metastasis (n=13).
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Figure 2. Kaplan–Meier curves in cervical cancers treated by CCRT. (A) Overall survival in cases with wild-type PIK3CA (n=52) versus mutant PIK3CA (n=7); (B)
Progression-free survival in cases with wild-type PIK3CA (n=52) versus mutant PIK3CA (n=7).
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more resistant to cisplatin/cisplatin + radiation than HeLa or
SiHa cells with wild-type PIK3CA, and that HeLa cells stably
expressing E545K were more resistant to cisplatin/cisplatin +
radiation than cells with wild-type/depleted PIK3CA. Cells
expressing E545K showed constitutively activated PI3K pathway
and augmented cell migration and Pictilisib (GDC-0941) PI3K
inhibitor reversed these phenotypes. Clinical trials are warranted
to examine the efﬁcacy of PI3K inhibition combined with CCRT
in cervical cancers.
As mentioned above, PIK3CA mutation can be theoretically
involved both in radioresistance and cisplatin resistance.[3,4] Our
next question was which mechanism is primarily contributing to
the observed poor survival in our patients. If radioresistance by
mutated PIK3CA is the major mechanism, there should have
been more recurrences inside the irradiated ﬁelds in patients with
mutant PIK3CA than in those with wild type, but the result was
reverse (20% vs 56%; Table 3). Conversely, there were more
recurrences outside the irradiated ﬁelds in mutant than in wild
type (80% vs 52%; Table 3); hence, we presume that cisplatin
resistance may be the major mechanism for the survival impact of
PIK3CA mutation. Patients with cisplatin-resistant tumors will
have more recurrences outside the irradiated ﬁelds, which should
be more critical to prognosis than recurrences inside the
irradiated ﬁelds, and their recurrence therapies are mostly
platinum-based chemotherapies such as paclitaxel and carbo-
platin. This can explain why wild-type group had better survival
even though they included more of persistent diseases with no
response to CCRT (10% vs 0%; Table 3) who must have
responded more to platinum-based chemotherapy because of
platinum-sensitive recurrences. Indeed, by contrast with CSS and
OS, when we conducted adjusted multivariate analyses of
PIK3CA mutation for PFS, only trends without statistical
signiﬁcance were observed (Table 4), most likely reﬂecting the
prognostic impact of PIK3CA mutation on sensitivity to
recurrence therapies. These ﬁndings may suggest that patients
would beneﬁt from PI3K inhibitors combined with not only
CCRT but also with systemic chemotherapies for recurrence.
Further clinical and basic studies are required to clarify this issue.
In conclusion, we have demonstrated here that PIK3CA
mutation is a signiﬁcant prognostic factor for poor OS and CSS in
cervical cancers treated by CCRTwith weekly cisplatin. Together
with the previously published ﬁndings, the current observations
further suggest that molecular inhibitors targeting the PI3K/Akt
pathway may improve the outcome by cisplatin-based CCRT in
locally advanced cervical cancers harboring PIK3CA mutation.
We believe that further basic and clinical research will help
develop novel treatment strategies and improve the still poor
prognosis of patients with locally advanced cervical cancer.
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